

November 15, 2018

FOR IMMEDIATE RELEASE

CONTACT: David L. Gordon, CEO
david@CNADiagnostics.com or +1.403.910.1834

CNA Diagnostics Adds to Scientific Advisory Board

Expands Leadership to Advance CNA Rapid Sepsis Dx through FDA Approval, and Commercial Licensing

Calgary, Alberta – CNA Diagnostics Inc. today announced it has added significant industry expertise to its Scientific Advisory Board in support of its product development pipeline including U.S. clinical trials for its diagnostic test for human sepsis, known as CNA Rapid Sepsis Dx.

In proof-of-concept studies, CNA Rapid Sepsis Dx has proven capable of detecting bacterial and fungal human sepsis in advance of clinical symptoms, using blood serum and processed on industry standard RT-PCR equipment for turn-around of results in approximately four hours on site at a hospital or medical clinic.

The following industry experts have agreed to join CNA Diagnostic's Scientific Advisory Board:

Dr. Robert Sherwin: is the Clinical Research Director for Sinai Grace Department of Emergency Medicine and serves as the Chief Science Officer of ResearchOne at Wayne State University in Detroit, Michigan. He has extensive clinical research experience in the fields of sepsis, resuscitation, emergency medicine, shock, hyperbaric medicine and hemodynamic monitoring. Dr. Sherwin is well published and has lectured nationally and internationally on infectious disease, sepsis, and many other topics.

Dr. Gary Clark, Ph.D.: is a mathematical and statistical expert with +40 years experience including progressive clinical operational responsibilities in oncology, with a focus in biostatistics, clinical data management, statistical programming, clinical operations and systems, and medical writing. He has participated in the FDA approval of advanced non-small lung cancer and advanced pancreatic cancer therapies. Dr. Clark's was a faculty member at the University of Colorado School of Medicine, Baylor College of Medicine/Breast Center and the University of Texas Health Center, San Antonio Department of Medicine/Oncology. Dr. Clark is one of the 100 most published breast cancer researchers.

Mr. Lyle Middendorf: is a scientific instrumentation expert with +40 years experience at LI-COR Inc., bringing expertise in engineering, marketing, research and development, of scientific instrumentation to Scientific Advisory Board. LI-COR designs, manufactures, and markets instruments for biological and environmental research globally, and provided, for example, the automated DNA sequencing machines used by scientists mapping the human genome. Mr. Middendorf is an electrical engineer by training and presently serves as the CTO of medical devices at LI-COR. He is well published on fluorescence and its use in diagnostics.

Dr. Keith Richter: is a small animal veterinarian with +30 years of experience and is nationally recognized for his interests in gastroenterology and liver disease. He is the founder of the Veterinary Specialty Hospital of San Diego, a co-founder of Ethos Veterinary Health, and serves as the Chief Applied Sciences Officer of Ethos Veterinary Health with a focus to build the Ethos Diagnostic Science laboratory division. Dr. Richter has authored several scientific articles and textbook chapters and lectures frequently nationally and internationally. He has collaborated with gastroenterology programs at the Boston University School of Medicine, Massachusetts Institute of Technology, UC San Diego Medical Center and Scripps Memorial Hospital. Dr. Richter is on the Board of Regents of the American College of Veterinary Internal Medicine.

Dr. David Chalack: is a veterinarian with +40 years experience in the livestock industry including large animal veterinary practices, dairy herd health, and animal health with a specialization in genetics and reproduction, and recognized expertise in dairy cattle husbandry and global international sales and marketing experience. Dr. Chalack is well connected with the North American livestock and dairy industry as well as the Canadian Food Inspection Agency. Dr. Chalack will chair the Scientific Advisory Board and is a member of the Institute of Corporate Directors.

Dr. Christoph W. Sensen, Chief Scientific Officer of CNA Diagnostics Inc. will be a member of the Scientific Advisory Board. CEO **David Gordon** will attend as an ex officio member.

“We are very pleased to have attracted such a slate of world renowned experts to join our scientific advisory board,” said David Gordon, CEO of CNA Diagnostics Inc.. “This core committee will provide CNA Diagnostics with invaluable guidance as we develop a multitude of diagnostic products to serve key market needs”.

About CNA Diagnostics:

CNA Diagnostics Inc. is a molecular diagnostics company focused on the development of diagnostic tests for the early detection of the presence of disease in humans and animals (mammals). The company has its headquarters in Calgary, Alberta, Canada. Test development is focused on disease stages prior to the onset of observable clinical symptoms, which currently cannot be detected reliably with existing commercially available methods. The company commercializes its tests primarily by licensing its technology to strategic partners for manufacturing, sales, distribution and service to end users in regions around the world.

Forward-Looking Information Advisory:

Certain information in this press release is forward-looking within the meaning of certain securities laws, and is subject to important risks, uncertainties and assumptions. This forward-looking information includes, among other things, information with respect to the Corporate Changes, assumptions about future economic conditions and courses of action, clinical trials, regulatory approvals, commercial plans, and the Company’s beliefs, plans, expectations, anticipations, estimates, and intentions. The words “may”, “could”, “should”, “would”, “suspect”, “outlook”, “believe”, “anticipate”, “estimate”, “expect”, “intend”, “plan”, “target” and similar words and expressions are used to identify forward-looking information. The forward-looking information in this news release describes the Company’s expectations as of the date of this news release and accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While the Company may elect to, it does not undertake to update this information at any particular time.

###